StemCell Therapy

Wall Street analysts expect that Tandem Diabetes Care Inc (NASDAQ:TNDM) will report earnings of ($0.08) per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Tandem Diabetes Care's earnings. The highest EPS estimate is $0.05 and the lowest is ($0.18). Tandem Diabetes Care reported earnings per share of ($0.13) in the same quarter last year, which suggests a positive year-over-year growth rate of 38.5%. The company is expected to report its next earnings report on Monday, November 2nd.

According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($0.52) per share for the current year, with EPS estimates ranging from ($0.59) to ($0.43). For the next financial year, analysts expect that the company will post earnings of $0.02 per share, with EPS estimates ranging from ($0.47) to $0.33. Zacks Investment Research's EPS calculations are a mean average based on a survey of sell-side analysts that follow Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by ($0.21). Tandem Diabetes Care had a negative return on equity of 12.88% and a negative net margin of 10.29%. The company had revenue of $109.24 million for the quarter, compared to analyst estimates of $86.51 million.

A number of research firms have recently commented on TNDM. Craig Hallum increased their target price on shares of Tandem Diabetes Care from $102.00 to $140.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Citigroup raised shares of Tandem Diabetes Care from a "neutral" rating to a "buy" rating and increased their target price for the stock from $94.00 to $120.00 in a report on Monday, July 6th. Piper Sandler upped their price target on Tandem Diabetes Care from $90.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Lake Street Capital upped their price target on Tandem Diabetes Care from $125.00 to $137.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Finally, Cowen increased their target price on Tandem Diabetes Care from $85.00 to $110.00 and gave the company an "outperform" rating in a research report on Tuesday, July 7th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Tandem Diabetes Care has an average rating of "Buy" and an average price target of $112.57.

Wall Street legend who picked Apple in 2003 and Bitcoin in 2016 shares his #1 pick for 2020s.

Shares of NASDAQ:TNDM traded up $1.62 during trading on Friday, reaching $112.96. The stock had a trading volume of 518,729 shares, compared to its average volume of 873,327. The firm's fifty day moving average is $102.77 and its 200 day moving average is $84.08. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.18 and a current ratio of 4.72. Tandem Diabetes Care has a 52 week low of $43.69 and a 52 week high of $114.00. The stock has a market cap of $6.88 billion, a price-to-earnings ratio of -150.61 and a beta of 0.56.

In other news, Director Kim D. Blickenstaff sold 50,000 shares of the firm's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $95.57, for a total transaction of $4,778,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Leigh Vosseller sold 20,000 shares of the firm's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $97.74, for a total value of $1,954,800.00. Following the transaction, the chief financial officer now owns 14,520 shares in the company, valued at approximately $1,419,184.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 432,530 shares of company stock worth $44,983,347. Insiders own 6.00% of the company's stock.

A number of hedge funds have recently modified their holdings of the stock. Handelsbanken Fonder AB bought a new stake in Tandem Diabetes Care during the second quarter valued at about $1,029,000. Stephens Investment Management Group LLC boosted its position in Tandem Diabetes Care by 9.4% during the second quarter. Stephens Investment Management Group LLC now owns 619,124 shares of the medical device company's stock valued at $61,244,000 after purchasing an additional 53,112 shares in the last quarter. Copper Rock Capital Partners LLC bought a new stake in Tandem Diabetes Care during the second quarter valued at about $12,279,000. Gladstone Institutional Advisory LLC boosted its position in Tandem Diabetes Care by 17.4% during the second quarter. Gladstone Institutional Advisory LLC now owns 4,424 shares of the medical device company's stock valued at $438,000 after purchasing an additional 655 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in Tandem Diabetes Care by 9.4% during the second quarter. AQR Capital Management LLC now owns 41,487 shares of the medical device company's stock valued at $4,104,000 after purchasing an additional 3,579 shares in the last quarter. 91.73% of the stock is currently owned by institutional investors.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Story: How to read a candlestick chart

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected]

7 Stocks That Prove Dividends Matter

Dividends can be an equalizing factor when comparing stocks. For example, you can be looking at one stock that is up 5% and another that is up 7% over a period of time. However, the stock that is up 5% pays a dividend while the one that pays 7% does not. That dividend factors into the stocks total return. Therefore although the former would appear to offer a better return, the stock that pays a dividend may actually provide a higher total return.

Dividends are a portion of a companys profit reflected as a percentage. However, this percentage changes with the companys stock price. For that reason, a common mistake investors make is to chase a yield. But a company that pays a 4% dividend yield may be a far better investment than a company with an 8% yield. Heres why.

The most important attribute of a dividend is its reliability. Getting a solid dividend one year has very little meaning if the company has to suspend, or cut, its dividend the next year. Investors want to own stocks in companies that have a solid history of paying a regular dividend.Another important consideration is a companys ability to increase its dividend. This means that the company is increasing the amount of the dividend regardless of stock price. Companies that do this over a specific period of time have achieved a special status. Dividend Aristocrats are companies that have increased their dividend every year for at least the last 25 years. Dividend Kings have increased their dividends every year for at least the last 50 years.

In this presentation, we highlight seven companies that offer a nice dividend and the opportunity for decent growth.

Click on Continue to view the 7 Stocks That Prove Dividends Matter.

View the "7 Stocks That Prove Dividends Matter".

See the rest here:
Tandem Diabetes Care Inc (NASDAQ:TNDM) Expected to Post Earnings of -$0.08 Per Share - MarketBeat

This entry was posted on August 30, 2020 at 7:55 pm and is filed under Diabetes. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |